Yves Allenbach

List of Publications by Year
in descending order

78 papers	4,948 citations	126907 33 h-index	102487 66 g-index
82 all docs	82 docs citations	82 times ranked	4340 citing authors

#	Article	IF	Citations
1	Long-term observational study of sporadic inclusion body myositis. Brain, 2011, 134, 3176-3184.	7.6	319
2	Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies. JAMA Neurology, 2018, 75, 1528.	9.0	301
3	Abatacept for Severe Immune Checkpoint Inhibitorâ€“Associated Myocarditis. New England Journal of Medicine, 2019, 380, 2377-2379.	27.0	296
4	Myocarditis in the Setting of Cancer Therapeutics. Circulation, 2019, 140, 80-91.	1.6	278
5	Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology, 2018, 91, e985-e994.	1.1	247
6	Anti-HMGCR Autoantibodies in European Patients With Autoimmune Necrotizing Myopathies. Medicine (United States), 2014, 93, 150-157.	1.0	235
7	JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain, 2018, 141, 1609-1621.	7.6	169
8	EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Annals of the Rheumatic Diseases, 2021, 80, 36-48.	0.9	153
9	239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14â€“16 December 2018. Neuromuscular Disorders, 2020, 30, 70-92.	0.6	148
10	Different phenotypes in dermatomyositis associated with anti-MDA5 antibody. Neurology, 2020, 95, e70-e78.	1.1	142
11	Immune Checkpoint Inhibitorâ€“Associated Myositis. Circulation, 2018, 138, 743-745.	1.6	139
12	Necrosis in anti-SRP ⁺ and anti-HMGCR ⁺ myopathies. Neurology, 2018, 90, e507-e517.	1.1	132
13	Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nature Reviews Rheumatology, 2020, 16, 689-701.	8.0	131
14	Pathogenic role of antiâ€“signal recognition protein and antiâ€“3â€Hydroxyâ€3â€methylglutarylâ€<scp>C</scp>o<scp>A</scp> reductase antibodies in necrotizing myopathies: Myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies. Annals of Neurology, 2017, 81, 538-548.	5.3	112
15	Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study. Autoimmunity Reviews, 2016, 15, 983-993.	5.8	105
16	<i>In vivo</i>pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy. Annals of the Rheumatic Diseases, 2019, 78, 131-139.	0.9	97
17	Advances in serological diagnostics of inflammatory myopathies. Current Opinion in Neurology, 2016, 29, 662-673.	3.6	96
18	Nuclear actin aggregation is a hallmark of anti-synthetase syndromeâ€“induced dysimmune myopathy. Neurology, 2015, 84, 1346-1354.	1.1	90

#	Article	IF	Citations
19	Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. Autoimmunity Reviews, 2020, 19, 102586.	5.8	80
20	Dermatomyositis With or Without Anti-Melanoma Differentiation-Associated Gene 5 Antibodies. American Journal of Pathology, 2016, 186, 691-700.	3.8	78
21	IFN-Î²-induced reactive oxygen species and mitochondrial damage contribute to muscle impairment and inflammation maintenance in dermatomyositis. Acta Neuropathologica, 2017, 134, 655-666.	7.7	78
22	Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation. Drug Safety, 2019, 42, 813-825.	3.2	78
23	Anti-HMGCR myopathy may resemble limb-girdle muscular dystrophy. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e523.	6.0	66
24	Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitorâ€“Associated Myocarditis. JAMA Cardiology, 2021, 6, 1329.	6.1	64
25	Development of a multivariate prediction model of intensive care unit transfer or death: A French prospective cohort study of hospitalized COVID-19 patients. PLoS ONE, 2020, 15, e0240711.	2.5	54
26	Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance. Annual Review of Pharmacology and Toxicology, 2021, 61, 85-112.	9.4	50
27	Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy. Autoimmunity Reviews, 2019, 18, 223-230.	5.8	44
28	The role of interferons type I, II and III in myositis: A review. Brain Pathology, 2021, 31, e12955.	4.1	44
29	Non-invasive differentiation of idiopathic inflammatory myopathy with cardiac involvement from acute viral myocarditis using cardiovascular magnetic resonance imaging T1 and T2 mapping. Journal of Cardiovascular Magnetic Resonance, 2018, 20, 11.	3.3	42
30	PD1 pathway in immune-mediated myopathies. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e558.	6.0	42
31	Sequestosomeâ€1 (p62) expression reveals chaperoneâ€assisted selective autophagy in immuneâ€mediated necrotizing myopathies. Brain Pathology, 2020, 30, 261-271.	4.1	42
32	Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study. Pharmaceuticals, 2020, 13, 317.	3.8	40
33	Rituximab in the Treatment of Refractory Anti-HMGCR Immune-mediated Necrotizing Myopathy. Journal of Rheumatology, 2019, 46, 623-627.	2.0	36
34	The IgG2 Isotype of Antiâ€“Transcription Intermediary Factor 1Î³ Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis. Arthritis and Rheumatology, 2019, 71, 1360-1370.	5.6	33
35	Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis. Journal of Neuromuscular Diseases, 2018, 5, 241-249.	2.6	31
36	Muscle Shear Wave Elastography in Inclusion Body Myositis: Feasibility, Reliability and Relationships with Muscle Impairments. Ultrasound in Medicine and Biology, 2018, 44, 1423-1432.	1.5	30

#	Article	IF	Citations
37	Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. , 2022, 10, e004699.		29
38	Severe axial and pelvifemoral muscle damage in immune-mediated necrotizing myopathy evaluated by whole-body MRI. Seminars in Arthritis and Rheumatism, 2020, 50, 1437-1440.	3.4	28
39	MRI and muscle imaging for idiopathic inflammatory myopathies. Brain Pathology, 2021, 31, e12954.	4.1	27
40	Antiphospholipid antibodies and thrombotic events in COVID-19 patients hospitalized in medicine ward. Autoimmunity Reviews, 2021, 20, 102729.	5.8	26
41	Analysis of cell surface and intranuclear markers on non-stimulated human PBMC using mass cytometry. PLoS ONE, 2018, 13, e0194593.	2.5	26
42	CD8+T-bet+ cells as a predominant biomarker for inclusion body myositis. Autoimmunity Reviews, 2019, 18, 325-333.	5.8	21
43	Granulomatosis-associated myositis. Neurology, 2020, 94, e910-e920.	1.1	21
44	Comparison of MR T1 and T2 mapping parameters to characterize myocardial and skeletal muscle involvement in systemic idiopathic inflammatory myopathy (IIM). European Radiology, 2019, 29, 5139-5147.	4.5	19
45	Global versus individual muscle segmentation to assess quantitative MRI-based fat fraction changes in neuromuscular diseases. European Radiology, 2021, 31, 4264-4276.	4.5	19
46	Reliability, validity and responsiveness of physical activity monitors in patients with inflammatory myopathy. Rheumatology, 2021, 60, 5713-5723.	1.9	17
47	The seasonality of Dermatomyositis associated with anti-MDA5 antibody: An argument for a respiratory viral trigger. Autoimmunity Reviews, 2021, 20, 102788.	5.8	17
48	Anti-mitochondrial antibodies are not a hallmark of severity in idiopathic inflammatory myopathies. Joint Bone Spine, 2018, 85, 375-376.	1.6	14
49	Anti-RNP antibodies delineate a subgroup of myositis: A systematic retrospective study on 46 patients. Autoimmunity Reviews, 2020, 19, 102465.	5.8	14
50	Relationship between change in physical activity and in clinical status in patients with idiopathic inflammatory myopathy: A prospective cohort study. Seminars in Arthritis and Rheumatism, 2020, 50, 1140-1149.	3.4	14
51	Mass cytometry reveals an impairment of B cell homeostasis in anti-synthetase syndrome. Journal of Neuroimmunology, 2019, 332, 212-215.	2.3	13
52	Edematous myositis: a clinical presentation first suggesting dermatomyositis diagnosis. Brain Pathology, 2020, 30, 867-876.	4.1	13
53	18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging for the diagnosis of immune checkpoint inhibitor-associated myocarditis. Archives of Cardiovascular Diseases, 2022, 115, 114-116.	1.6	13
54	256th ENMC international workshop: Myositis specific and associated autoantibodies (MSA-ab): Amsterdam, The Netherlands, 8-10 October 2021. Neuromuscular Disorders, 2022, 32, 594-608.	0.6	13

#	Article	IF	Citations
55	Correspondence on â€˜Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric surveyâ€™. Annals of the Rheumatic Diseases, 2023, 82, e30-e30.	0.9	11
56	Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database. Journal of Autoimmunity, 2020, 111, 102454.	6.5	11
57	NanoString technology distinguishes antiâ€•TIFâ€•1Î³⁺ from antiâ€•Miâ€•2⁺ dermatomyositis patients. Brain Pathology, 2021, 31, e12957.	4.1	11
58	Potential Pathogenic Role of Anti-Signal Recognition Protein and Anti-3-hydroxy-3-methylglutaryl-CoA Reductase Antibodies in Immune-Mediated Necrotizing Myopathies. Current Rheumatology Reports, 2018, 20, 56.	4.7	10
59	Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. PLoS ONE, 2020, 15, e0242306.	2.5	10
60	Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. Therapie, 2021, 76, 285-295.	1.0	8
61	NK Cell Patterns in Idiopathic Inflammatory Myopathies with Pulmonary Affection. Cells, 2021, 10, 2551.	4.1	8
62	Extracorporeal life support allows lung transplant in anti-MDA5+ rapidly progressive interstitial lung disease. European Respiratory Journal, 2022, 59, 2102968.	6.7	8
63	Responsiveness to Change of 5-point MRC scale, Endurance and Functional Evaluation for Assessing Myositis in Daily Clinical Practice. Journal of Neuromuscular Diseases, 2019, 6, 99-107.	2.6	7
64	Expanding the spectrum of HIV-associated myopathy. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1296-1298.	1.9	7
65	Endoplasmic reticulumâ€•stress and unfolded protein responseâ€•activation in immuneâ€•mediated necrotizing myopathy. Brain Pathology, 2022, 32, .	4.1	7
66	Peripheral neuropathy and livedoid vasculopathy. Journal of Neurology, 2022, 269, 3779-3788.	3.6	6
67	Cytokine profile as a prognostic tool in coronavirus disease 2019. Comment on â€œUrgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndromeâ€•by Quartuccio et al. Joint Bone Spine. 2020;87:191â€“93. Joint Bone Spine, 2021, 88, 105074.	1.6	5
68	Reply: A child with severe juvenile dermatomyositis treated with ruxolitinib. Brain, 2018, 141, e81-e81.	7.6	4
69	Positioning of myositis-specific and associated autoantibody (MSA/MAA) testing in disease criteria and routine diagnostic work-up. Journal of Translational Autoimmunity, 2022, 5, 100148.	4.0	4
70	Reply: Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. Brain, 2019, 142, e60-e60.	7.6	3
71	Reply: Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis. Brain, 2019, 142, e9-e9.	7.6	1
72	Echocardiography and renin-aldosterone interplay as predictors of death in COVID-19. Archives of Cardiovascular Diseases, 2022, 115, 96-96.	1.6	1

#	Article	IF	Citations
73	Infliximab as effective treatment for aseptic neutrophilic myositis. Neurology, 2019, 93, 1009-1011.	1.1	0
74	Response to: â€˜On using machine learning algorithms to define clinically meaningful patient subgroupsâ€™ by Pinal-Fernandez and Mammen. Annals of the Rheumatic Diseases, 2020, 79, e130-e130.	0.9	0
75	Title is missing!. , 2020, 15, e0240711.		0
76	Title is missing!. , 2020, 15, e0240711.		0
77	Title is missing!. , 2020, 15, e0240711.		0
78	Title is missing!. , 2020, 15, e0240711.		0